文献速递新发突发、热带与寄生虫病

妊娠期非复杂性恶性疟的青蒿素类与奎宁类治疗疗效及耐受性:系统综述与个体患者数据Meta分析

Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis.
PubMed 文献 · Lancet Infect Dis · 2020-04-29

该系统综述与个体患者数据Meta分析纳入19项研究共4968例妊娠期疟疾发作,比较青蒿素类或奎宁类方案的PCR校正疗效与耐受性。以蒿甲醚-苯芴醇为参照,奎宁单药治疗失败风险更高,而青蒿琥酯-阿莫地喹、青蒿琥酯-甲氟喹和双氢青蒿素-哌喹的失败风险更低;奎宁类治疗后第7天配子体携带风险更高。

要点

  • 妊娠期非复杂性恶性疟首选青蒿素联合疗法,奎宁单药疗效较差。
  • 双氢青蒿素-哌喹、青蒿琥酯-阿莫地喹和青蒿琥酯-甲氟喹的疗效优于蒿甲醚-苯芴醇。
  • 奎宁类治疗后第7天配子体携带风险显著高于青蒿素类。

核心结论

  • 妊娠期青蒿素联合疗法(ACTs)的疗效与耐受性优于奎宁。
  • 蒿甲醚-苯芴醇疗效低于其他ACTs,可能需要剂量优化。

研究设计与样本

  • 系统综述与个体患者数据(IPD)Meta分析,检索7个数据库和2个临床试验注册库至2019年4月26日。
  • 纳入19项评估妊娠期PCR校正疗效且随访≥28天的干预性或观察性队列研究,代表文献中4968/5360例发作(92%)。
  • 采用随机效应Cox和logistic回归的一阶段IPD Meta分析,以蒿甲醚-苯芴醇为参照。

临床怎么用

  • 妊娠期非复杂性恶性疟应优先选择ACTs而非奎宁单药。
  • 蒿甲醚-苯芴醇疗效相对较低,临床可考虑其他ACTs或剂量优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malaria in pregnancy affects both the mother and the fetus. However, evidence supporting treatment guidelines for uncomplicated (including asymptomatic) falciparum malaria in pregnant women is scarce and assessed in varied ways. We did a systematic literature review and individual patient data (IPD) meta-analysis to compare the efficacy and tolerability of different artemisinin-based or quinine-based treatments for malaria in pregnant women. METHODS: We did a systematic review of interventional or observational cohort studies assessing the efficacy of artemisinin-based or quinine-based treatments in pregnancy. Seven databases (MEDLINE, Embase, Global Health, Cochrane Library, Scopus, Web of Science, and Literatura Latino Americana em Ciencias da Saude) and two clinical trial registries (International Clinical Trials Registry Platform and ClinicalTrials.gov) were searched. The final search was done on April 26, 2019. Studies that assessed PCR-corrected treatment efficacy in pregnancy with follow-up of 28 days or more were included. Investigators of identified studies were invited to share data from individual patients. The outcomes assessed included PCR-corrected efficacy, PCR-uncorrected efficacy, parasite clearance, fever clearance, gametocyte development, and acute adverse events. One-stage IPD meta-analysis using Cox and logistic regression with random-effects was done to estimate the risk factors associated with PCR-corrected treatment failure, using artemether-lumefantrine as the reference. This study is registered with PROSPERO, CRD42018104013. FINDINGS: Of the 30 studies assessed, 19 were included, representing 92% of patients in the literature (4968 of 5360 episodes). Risk of PCR-corrected treatment failure was higher for the quinine monotherapy (n=244, adjusted hazard ratio [aHR] 6·11, 95% CI 2·57-14·54, p<0·0001) but lower for artesunate-amodiaquine (n=840, 0·27, 95% 0·14-0·52, p<0·0001), artesunate-mefloquine (n=1028, 0·56, 95% 0·34-0·94, p=0·03), and dihydroartemisinin-piperaquine (n=872, 0·35, 95% CI 0·18-0·68, p=0·002) than artemether-lumefantrine (n=1278) after adjustment for baseline asexual parasitaemia and parity. The risk of gametocyte carriage on day 7 was higher after quinine-based therapy than artemisinin-based treatment (adjusted odds ratio [OR] 7·38, 95% CI 2·29-23·82). INTERPRETATION: Efficacy and tolerability of artemisinin-based combination therapies (ACTs) in pregnant women are better than quinine. The lower efficacy of artemether-lumefantrine compared with other ACTs might require dose optimisation. FUNDING: The Bill & Melinda Gates Foundation, ExxonMobil Foundation, and the University of Oxford Clarendon Fund.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Saito M, Mansoor R, Kennon K, et al. Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2020. PMID: 32530424. doi:10.1016/S1473-3099(20)30064-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。